Table 2.
Dysregulated microRNAs in the plasma/serum of patients with HBV-related HCC.
| miRNAs | Dysregulation type | Fold change | Case vs. control | Samples details | References |
|---|---|---|---|---|---|
| miR-18a | Up-regulated | NA | HCC vs. HC, HCC vs. (CHB + LC) | 101 HBV-HCC, 30 CHB or HBV-LC, 60 HC | (44) |
| miR-192 | Up-regulated | 1.4b | HCC vs. (LC+CHB+HC) | 457 HBV-HCC, 141 HBV-LC, 169 CHB, 167 HC | (45) |
| miR-206 | Up-regulated | 9.94b | HCC vs. HC | 261 HBV-HCC, 173 HC | (46) |
| Up-regulated | 3.51b | HCC vs. LC | 261 HBV-HCC, 233 HBV-LC | (46) | |
| Up-regulated | 2.98 ± 3.94b | HCC vs. matched control | 55 HBV-HCC, 50 age and gender-matched control | (39) | |
| miR-221 | Up-regulated | 4.83b | HCC vs. HC | 46 HCC (30 HBV), 20 HC | (41) |
| miR-222 | Up-regulated | NA | HCC vs. HC | 70 HBV-HCC, 48 CHB, 34 HC | (43) |
| Up-regulated | 3.01b | HCC vs. HC | 46 HCC (30 HBV), 20 HC | (41) | |
| miR-224 | Up-regulated | 1.88b | HCC vs. HC | 46 HCC (30 HBV), 20 HC | (41) |
| miR-21 | Up-regulated | 1.9b | HCC vs. (LC+CHB+HC) | 457 HBV-HCC, 141 HBV-LC, 169 CHB, 167 HC | (45) |
| Up-regulated | NA | HCC vs. HC | 97 HCC (60 HBV), 30 HC | (47) | |
| Up-regulated | 2.85b | HCC vs. HC | 46 HCC (30 HBV), 20 HC | (41) | |
| Up-regulated | NA | HCC vs. HC | 101 HCC (76 HBV), 48 CHB, 89 HC | (42) | |
| Down-regulated | NA | HCC vs. CHB | 101 HCC (76 HBV), 48 CHB, 89 HC | (42) | |
| miR-122 | Up-regulated | 4.09 ± 5.38 b | HCC vs. HBV (ASC +CHB) | 65 HBV-HCC, 160 controls | (39) |
| Up-regulated | NA | HCC vs. HC | 70 HBV-HCC, 48 CHB, 34 HC | (43) | |
| Up-regulated | NA | HCC vs. HC | 101 HCC (76 HBV), 48 CHB, 89 HC | (42) | |
| Down-regulated | 0.7b | HCC vs. (LC+CHB+HC) | 457 HBV-HCC, 141 HBV-LC, 169 CHB, 167 HC | (45) | |
| Down-regulated | NA | HCC vs. CHB | 101 HCC (76 HBV), 48 CHB, 89 HC | (42) | |
| miR-192-5p | Up-regulated | 1.71b | HCC vs. HC | 212 HBV-HCC, 110 HC | (48) |
| Up-regulated | 1.97b | HCC vs. LC | 212 HBV-HCC, 106 HBV-LC | (48) | |
| Down-regulated | 0.85b | HCC vs. LC | 261 HBV-HCC, 233 HBV-LC | (46) | |
| Down-regulated | 0.77b | HCC vs. HC | 261 HBV-HCC, 173 HC | (46) | |
| miR-223 | Up-regulated | NA | HCC vs. HC | 101 HCC (76 HBV), 89 HC | (42) |
| Up-regulated | 2.97 ± 1.67 b | HCC vs. HC | 65 HBV-HCC, 160 controls | (39) | |
| Up-regulated | NA | HCC vs. HC | 70 HBV-HCC, 34 HC | (43) | |
| No difference | NA | HCC vs. CHB | 101 HCC (76 HBV), 48 CHB | (42) | |
| Down-regulated | 0.3b | HCC vs. (LC+CHB+HC) | 457 HBV-HCC, 141 HBV-LC, 169 CHB, 167 HC | (45) | |
| Down-regulated | NA | HCC vs. HBV (ASC +CHB) | 65 HBV-HCC, 135 HBV (55 ASC+ 80 CHB) | (39) | |
| miR-26a | Down-regulated | 0.2b | HCC vs. (LC+CHB+HC) | 457 HBV-HCC, 141 HBV-LC, 169 CHB, 167 HC | (45) |
| miR-26a-5p | Down-regulated | 0.65b | HCC vs. HC | 261 HBV-HCC, 173 HC | (46) |
| Down-regulated | 0.54b | HCC vs. LC | 261 HBV-HCC, 233 HBV-LC | (46) | |
| miR-122-5p | Down-regulated | 0.27b | HCC vs. HC | 261 HBV-HCC, 173 HC | (46) |
| Down-regulated | 0.54b | HCC vs. LC | 261 HBV-HCC, 233 HBV-LC | (46) | |
| miR-125b | Down-regulated | 0.26 ± 0.46b | HCC vs. HBV (ASC +CHB) | 65 HBV-HCC, 135 HBV (55 ASC+ 80 CHB) | (39) |
| Down-regulated | NA | HCC vs. LC | 30 HCC (28 HBV), 30 LC (27 HBV) | (40) | |
| Down-regulated | NA | HCC vs. CHB | 30 HCC (28 HBV), 30 CHB | (40) | |
| miR-199a-5p | Down-regulated | 0.58b | HCC vs. HC | 261 HBV-HCC, 173 HC | (46) |
| Down-regulated | 0.87b | HCC vs. LC | 261 HBV-HCC, 233 HBV-LC | (46) |
Fold changes were based on the original report;
a
Log2 fold change.
b
Regular fold change.
ASC, asymptomatic carrier; CHB, chronic hepatitis B; HBV, Hepatitis B virus; HBV-HCC, HBV-related HCC; HBV-LC, HBV-related LC; HC, healthy control; HCC, hepatocellular carcinoma; LC, liver cirrhosis; NA, not available.